BACKGROUND: A safe and effective vaccine for the prevention of human immunodeficiency virus type 1 (HIV-1) infection is a global priority. We tested the efficacy of a DNA prime-recombinant adenovirus type 5 boost (DNA/rAd5) vaccine regimen in persons at increased risk for HIV-1 infection in the United States. METHODS: At 21 sites, we randomly assigned 2504 men or transgender women who have sex with men to receive theDNA/rAd5 vaccine (1253 participants) orplacebo (1251 participants). We assessed HIV-1 acquisition from week 28 through month 24 (termed week 28+ infection), viral-load set point (mean plasma HIV-1 RNA level 10 to 20 weeks after diagnosis), and safety. The 6-plasmid DNA vaccine (expressing clade B Gag, Pol, and Nef and Env proteins from clades A, B, and C) was administered at weeks 0, 4, and 8. The rAd5 vector boost (expressing clade B Gag-Pol fusion protein and Env glycoproteins from clades A, B, and C) was administered at week 24. RESULTS: In April 2013, the data and safety monitoring board recommended halting vaccinations for lack of efficacy. The primary analysis showed that week 28+ infection had been diagnosed in 27 participants in the vaccine group and 21 in the placebo group (vaccine efficacy, -25.0%; 95% confidence interval, -121.2 to 29.3; P=0.44), with mean viral-load set points of 4.46 and 4.47 HIV-1 RNA log10 copies per milliliter, respectively. Analysis of all infections during the study period (41 in the vaccine group and 31 in the placebo group) also showed lack of vaccine efficacy (P=0.28). The vaccine regimen had an acceptable side-effect profile. CONCLUSIONS: The DNA/rAd5 vaccine regimen did not reduce either the rate of HIV-1 acquisition or the viral-load set point in the population studied. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT00865566.).
RCT Entities:
BACKGROUND: A safe and effective vaccine for the prevention of human immunodeficiency virus type 1 (HIV-1) infection is a global priority. We tested the efficacy of a DNA prime-recombinant adenovirus type 5 boost (DNA/rAd5) vaccine regimen in persons at increased risk for HIV-1 infection in the United States. METHODS: At 21 sites, we randomly assigned 2504 men or transgender women who have sex with men to receive the DNA/rAd5 vaccine (1253 participants) or placebo (1251 participants). We assessed HIV-1 acquisition from week 28 through month 24 (termed week 28+ infection), viral-load set point (mean plasma HIV-1 RNA level 10 to 20 weeks after diagnosis), and safety. The 6-plasmid DNA vaccine (expressing clade B Gag, Pol, and Nef and Env proteins from clades A, B, and C) was administered at weeks 0, 4, and 8. The rAd5 vector boost (expressing clade B Gag-Pol fusion protein and Env glycoproteins from clades A, B, and C) was administered at week 24. RESULTS: In April 2013, the data and safety monitoring board recommended halting vaccinations for lack of efficacy. The primary analysis showed that week 28+ infection had been diagnosed in 27 participants in the vaccine group and 21 in the placebo group (vaccine efficacy, -25.0%; 95% confidence interval, -121.2 to 29.3; P=0.44), with mean viral-load set points of 4.46 and 4.47 HIV-1 RNA log10 copies per milliliter, respectively. Analysis of all infections during the study period (41 in the vaccine group and 31 in the placebo group) also showed lack of vaccine efficacy (P=0.28). The vaccine regimen had an acceptable side-effect profile. CONCLUSIONS: The DNA/rAd5 vaccine regimen did not reduce either the rate of HIV-1 acquisition or the viral-load set point in the population studied. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT00865566.).
Authors: Deborah Donnell; Jared M Baeten; James Kiarie; Katherine K Thomas; Wendy Stevens; Craig R Cohen; James McIntyre; Jairam R Lingappa; Connie Celum Journal: Lancet Date: 2010-05-26 Impact factor: 79.321
Authors: Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden Journal: N Engl J Med Date: 2010-11-23 Impact factor: 91.245
Authors: Barton F Haynes; Peter B Gilbert; M Juliana McElrath; Susan Zolla-Pazner; Georgia D Tomaras; S Munir Alam; David T Evans; David C Montefiori; Chitraporn Karnasuta; Ruengpueng Sutthent; Hua-Xin Liao; Anthony L DeVico; George K Lewis; Constance Williams; Abraham Pinter; Youyi Fong; Holly Janes; Allan DeCamp; Yunda Huang; Mangala Rao; Erik Billings; Nicos Karasavvas; Merlin L Robb; Viseth Ngauy; Mark S de Souza; Robert Paris; Guido Ferrari; Robert T Bailer; Kelly A Soderberg; Charla Andrews; Phillip W Berman; Nicole Frahm; Stephen C De Rosa; Michael D Alpert; Nicole L Yates; Xiaoying Shen; Richard A Koup; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Nelson L Michael; Jerome H Kim Journal: N Engl J Med Date: 2012-04-05 Impact factor: 91.245
Authors: Glenda E Gray; Mary Allen; Zoe Moodie; Gavin Churchyard; Linda-Gail Bekker; Maphoshane Nchabeleng; Koleka Mlisana; Barbara Metch; Guy de Bruyn; Mary H Latka; Surita Roux; Matsontso Mathebula; Nivashnee Naicker; Constance Ducar; Donald K Carter; Adrien Puren; Niles Eaton; M Julie McElrath; Michael Robertson; Lawrence Corey; James G Kublin Journal: Lancet Infect Dis Date: 2011-05-11 Impact factor: 25.071
Authors: Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming Journal: N Engl J Med Date: 2011-07-18 Impact factor: 91.245
Authors: Norman L Letvin; Srinivas S Rao; David C Montefiori; Michael S Seaman; Yue Sun; So-Yon Lim; Wendy W Yeh; Mohammed Asmal; Rebecca S Gelman; Ling Shen; James B Whitney; Cathal Seoighe; Miguel Lacerda; Sheila Keating; Philip J Norris; Michael G Hudgens; Peter B Gilbert; Adam P Buzby; Linh V Mach; Jinrong Zhang; Harikrishnan Balachandran; George M Shaw; Stephen D Schmidt; John-Paul Todd; Alan Dodson; John R Mascola; Gary J Nabel Journal: Sci Transl Med Date: 2011-05-04 Impact factor: 17.956
Authors: Hannah Kibuuka; Robert Kimutai; Leonard Maboko; Fred Sawe; Mirjam S Schunk; Arne Kroidl; Douglas Shaffer; Leigh Anne Eller; Rukia Kibaya; Michael A Eller; Karin B Schindler; Alexandra Schuetz; Monica Millard; Jason Kroll; Len Dally; Michael Hoelscher; Robert Bailer; Josephine H Cox; Mary Marovich; Deborah L Birx; Barney S Graham; Nelson L Michael; Mark S de Souza; Merlin L Robb Journal: J Infect Dis Date: 2010-02-15 Impact factor: 5.226
Authors: Walter Jaoko; Etienne Karita; Kayitesi Kayitenkore; Gloria Omosa-Manyonyi; Susan Allen; Soe Than; Elizabeth M Adams; Barney S Graham; Richard A Koup; Robert T Bailer; Carol Smith; Len Dally; Bashir Farah; Omu Anzala; Claude M Muvunyi; Jean Bizimana; Tony Tarragona-Fiol; Philip J Bergin; Peter Hayes; Martin Ho; Kelley Loughran; Wendy Komaroff; Gwynneth Stevens; Helen Thomson; Mark J Boaz; Josephine H Cox; Claudia Schmidt; Jill Gilmour; Gary J Nabel; Patricia Fast; Job Bwayo Journal: PLoS One Date: 2010-09-21 Impact factor: 3.240
Authors: Laurence Peiperl; Cecilia Morgan; Zoe Moodie; Hongli Li; Nina Russell; Barney S Graham; Georgia D Tomaras; Stephen C De Rosa; M Juliana McElrath Journal: PLoS One Date: 2010-10-27 Impact factor: 3.240
Authors: Gavin J Churchyard; Cecilia Morgan; Elizabeth Adams; John Hural; Barney S Graham; Zoe Moodie; Doug Grove; Glenda Gray; Linda-Gail Bekker; M Juliana McElrath; Georgia D Tomaras; Paul Goepfert; Spyros Kalams; Lindsey R Baden; Michelle Lally; Raphael Dolin; William Blattner; Artur Kalichman; J Peter Figueroa; Jean Pape; Mauro Schechter; Olivier Defawe; Stephen C De Rosa; David C Montefiori; Gary J Nabel; Lawrence Corey; Michael C Keefer Journal: PLoS One Date: 2011-08-03 Impact factor: 3.240
Authors: Catia T Perciani; Bashir Farah; Rupert Kaul; Mario A Ostrowski; Salaheddin M Mahmud; Omu Anzala; Walter Jaoko; Kelly S MacDonald Journal: J Clin Invest Date: 2019-01-22 Impact factor: 14.808
Authors: Shari N Gordon; Melvin N Doster; Rhonda C Kines; Brandon F Keele; Egidio Brocca-Cofano; Yongjun Guan; Poonam Pegu; Namal P M Liyanage; Monica Vaccari; Nicolas Cuburu; Christopher B Buck; Guido Ferrari; David Montefiori; Michael Piatak; Jeffrey D Lifson; Anastasia M Xenophontos; David Venzon; Marjorie Robert-Guroff; Barney S Graham; Douglas R Lowy; John T Schiller; Genoveffa Franchini Journal: J Immunol Date: 2014-11-14 Impact factor: 5.422
Authors: Laura Pattacini; Jared M Baeten; Katherine K Thomas; Tayler R Fluharty; Pamela M Murnane; Deborah Donnell; Elizabeth Bukusi; Allan Ronald; Nelly Mugo; Jairam R Lingappa; Connie Celum; M Juliana McElrath; Jennifer M Lund Journal: J Acquir Immune Defic Syndr Date: 2016-06-01 Impact factor: 3.731
Authors: Abigail J S Armstrong; Michael Shaffer; Nichole M Nusbacher; Christine Griesmer; Suzanne Fiorillo; Jennifer M Schneider; C Preston Neff; Sam X Li; Andrew P Fontenot; Thomas Campbell; Brent E Palmer; Catherine A Lozupone Journal: Microbiome Date: 2018-11-05 Impact factor: 14.650
Authors: Julie E Ledgerwood; Zonghui Hu; Pamela Costner; Galina Yamshchikov; Mary E Enama; Sarah Plummer; Cynthia S Hendel; Lasonji Holman; Brenda Larkin; Ingelise Gordon; Robert T Bailer; Donald M Poretz; Uzma Sarwar; Alisha Kabadi; Richard Koup; John R Mascola; Barney S Graham Journal: Contemp Clin Trials Date: 2015-08-12 Impact factor: 2.226